Stock analysts at TD Cowen assumed coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Get Free Report) in a research report issued to clients and investors on Tuesday, Briefing.com reports. The brokerage set a “buy” rating on the stock.
A number of other analysts have also recently commented on LYCA. Wall Street Zen upgraded shares of Lycia Therapeutics to a “hold” rating in a research report on Saturday, October 31st. Evercore began coverage on Lycia Therapeutics in a report on Tuesday. They set an “outperform” rating and a $43.00 target price on the stock. Jefferies Financial Group assumed coverage on Lycia Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 target price for the company. Finally, Guggenheim started coverage on Lycia Therapeutics in a report on Tuesday. They issued a “buy” rating and a $75.00 price target for the company. Four investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $56.00.
Get Our Latest Stock Report on Lycia Therapeutics
Lycia Therapeutics Trading Down 8.3%
LYCA opened at $28.61 on Tuesday. Lycia Therapeutics has a twelve month low of $22.19 and a twelve month high of $36.49.
Insider Activity
In related news, major shareholder Venrock Healthcare Capital Par acquired 8,305 shares of the stock in a transaction dated Monday, November 2nd. The stock was bought at an average price of $26.95 per share, with a total value of $223,819.75. Following the completion of the transaction, the insider directly owned 6,858,542 shares of the company’s stock, valued at approximately $184,837,706.90. The trade was a 0.12% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired a total of 2,078,749 shares of company stock worth $38,526,342 over the last ninety days.
Lycia Therapeutics Company Profile
Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.
Recommended Stories
- Five stocks we like better than Lycia Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
